Curis Expands Clinical Trial for CLL Treatment and Secures Shareholder Approval for Reverse Stock Split
Curis has initiated the enrollment phase for its TakeAim CLL trial, a crucial step in evaluating a novel therapeutic combination for chronic lymphocytic leukemia. This advancement, coupled with a strategic financial maneuver approved by shareholders, underscores the company's dual focus on clinical progress and market compliance.
Curis's recent endeavors highlight significant developments in both its clinical research pipeline and corporate governance. The company's primary focus remains on advancing its experimental treatments, particularly for hematologic malignancies, while also ensuring its financial standing meets regulatory requirements.
Clinical Advancement in CLL Treatment
Curis has announced the opening of 11 clinical centers for its Phase II TakeAim CLL study. This trial aims to evaluate the efficacy of emavusertib, an oral small molecule inhibitor, when administered in conjunction with zanubrutinib to individuals suffering from chronic lymphocytic leukemia. The company is actively moving forward with patient enrollment, and it projects that the first five participants will receive their initial doses by the close of July 2026. Preliminary findings from this study are anticipated to be available by December 2026, offering crucial insights into the potential of this therapeutic approach.
The TakeAim CLL study is designed as an open-label investigation, focusing on a dual inhibition strategy that targets nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB). This particular pathway is recognized as a pivotal factor in the progression of CLL. To be eligible for participation, patients must exhibit a partial response or a partial response with lymphocytosis, demonstrate positive measurable residual disease through the ClonoSEQ assay, and have undergone zanubrutinib treatment for a minimum of 12 months. This rigorous selection process ensures that the study population is well-defined, allowing for a precise evaluation of the treatment's impact on a relevant patient cohort.
Corporate Strategy and Shareholder Support
In parallel with its clinical strides, Curis has successfully secured shareholder approval for a reverse stock split proposal. This decision was made during a special meeting where stockholders endorsed an amendment to the company's Restated Certificate of Incorporation. The amendment allows for a reverse stock split of issued and outstanding shares within a ratio ranging from 1-for-5 to 1-for-25. The final ratio will be determined by the company's board of directors, and Curis has committed to announcing the specific ratio and effective date before the split is executed. This strategic financial move is intended to help Curis regain compliance with the NASDAQ bid price listing requirements, signaling a proactive approach to maintaining its market presence and investor confidence.
Curis President and CEO James Dentzer expressed satisfaction with both the operational advancements in the CLL study and the strong endorsement from shareholders, emphasizing the company's commitment to building on these achievements. Beyond the TakeAim CLL trial, Curis is also engaged in other significant clinical research. These include the TakeAim Lymphoma Phase I/II study, which combines emavusertib with ibrutinib for relapsed or refractory primary central nervous system lymphoma, as well as ongoing investigations into acute myeloid leukemia and myelodysplastic syndromes. Furthermore, emavusertib has previously been granted orphan drug designation by regulatory bodies in both the European Commission and the United States for various indications, underscoring its therapeutic potential and the recognized need for new treatments in these areas.
